Avidity Biosciences Receives Investment from CureDuchenne | DuchenneXchange

welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!

Avidity Biosciences Receives Investment from CureDuchenne


Avidity Biosciences, a privately held biotech company pioneering a new class of precision medicines based upon antibody-oligonucleotide conjugates, announced today that CureDuchenne has made an equity investment in the company. Funding will help to advance pre-clinical development of potential therapies to treat patients with Duchenne muscular dystrophy (DMD).

https://www.duchennexchange.org/wp-content/uploads/2018/07/CureDuchenne_logo_trans_lg-copy.png